A 6-month maintenance therapy with adapalene-benzoyl peroxide gel prevents relapse and continuously improves efficacy among patients with severe acne vulgaris: Results of a randomized controlled trial

British Journal of Dermatology

Volumn 164, Issue 6, 2011, Pages 1376-1382

  Poulin, Y ^a   Sanchez, N P ^b   Bucko, A ^c   Fowler, J ^d   Jarratt, M ^e   Kempers, S ^f   Kerrouche, N ^g   Dhuin, J C ^g   Kunynetz, R ^h  

^a Centre de Recherche Dermatologique du Québec Metropolitan   (Canada)

^b Sanchez Dermatology   (Puerto Rico)

^c Academic Dermatology Associates   (United States)

^d Dermatology Specialists   (United States)

^e DermResearch Inc   (United States)

^f Minnesota Clinical Study Center   (United States)

^g Galderma R and D   (France)

^h Ultranova Skincare   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPALENE PLUS BENZOYL PEROXIDE;

ACNE VULGARIS; ADOLESCENT; ADULT; ARTICLE; CHILD; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; ERYTHEMA; FEMALE; GEL; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SCHOOL CHILD; SKIN BURNING SENSATION; SKIN IRRITATION; TREATMENT DURATION; TREATMENT OUTCOME;

ACNE VULGARIS; ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADULT; BENZOYL PEROXIDE; CHILD; CHRONIC DISEASE; DERMATOLOGIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; GELS; HUMANS; MALE; NAPHTHALENES; RECURRENCE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79957615072     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2011.10344.x     Document Type: Article

References (29)

1. Gollnick H, Finlay A, Shear N,. Can we define acne as a chronic disease? Am J Clin Dermatol 2008; 9: 279-84.
2. Thiboutot D, Gollnick H, Bettoli V, et al. New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group. J Am Acad Dermatol 2009; 60 (5 Suppl.): S1-50.
3. Pawin H, Beylot C, Chivot M, et al. Physiopathology of acne vulgaris: recent data, new understanding of the treatments. Eur J Dermatol 2004; 14: 4-12. (Pubitemid 38187090)
4. Koo J,. How do you foster medication adherence for better acne vulgaris management? Skinmed 2003; 2: 229-33.
5. Liu A, Yang DJ, Gerhardstein PC, Hsu S,. Relapse of acne following isotretinoin treatment: a retrospective study of 405 patients. J Drugs Dermatol 2008; 7: 963-6.
6. Quéreux G, Volteau C, N'Guyen JM, Dréno B,. Prospective study of risk factors of relapse after treatment of acne with oral isotretinoin. Dermatology 2006; 212: 168-76. (Pubitemid 43260733)
7. Leyden JJ,. A review of the use of combination therapies for the treatment of acne vulgaris. J Am Acad Dermatol 2003; 49 (3 Suppl.): S200-10. (Pubitemid 37046534)
8. Gollnick H, Cunliffe W, Berson D, et al. Management of acne. A report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol 2003; 49 (1 Suppl.): S1-37. (Pubitemid 36791495)
9. Andres P, Pernin C, Poncet M,. Adapalene-benzoyl peroxide, a new fixed dose combination for the treatment of acne vulgaris: a randomized, bilateral (split-face), dose-assessment study of cutaneous tolerability in healthy subjects. Cutis 2008; 81: 278-84.
10. Thiboutot DM, Weiss J, Bucko A, et al. Adapalene-benzoyl peroxide, a fixed-dose combination for the treatment of acne vulgaris: results of a multicenter, randomized double-blind, controlled study. J Am Acad Dermatol 2007; 57: 791-9. (Pubitemid 47553072)
11. Stein Gold L, Tan J, Cruz-Santana A, et al. A North American study of adapalene-benzoyl peroxide combination gel in the treatment of acne. Cutis 2009; 84: 110-16.
12. Gollnick H, Draelos Z, Glenn MJ, et al. Adapalene-benzoyl peroxide, a unique fixed-dose combination topical gel for the treatment of acne vulgaris: a transatlantic, randomized, double-blind, controlled study in 1670 patients. Br J Dermatol 2009; 161: 1180-9.
13. Feldman SR, Tan J, Poulin Y, et al., The efficacy of adapalene-benzoyl peroxide combination increases with number of acne lesions. J Am Acad Dermatol 2011; doi: 10.1016/j.jaad.2010.03.036.
14. Stein Gold L, Cruz A, Eichenfield L, et al. Effective and safe combination therapy for severe acne vulgaris: a randomized, vehicle-controlled, double-blind study of adapalene 0·1%-benzoyl peroxide 2·5% fixed-dose combination gel with doxycycline hyclate 100 mg. Cutis 2010; 85: 94-104.
15. Leyden JJ, Del Rosso JQ, Webster GF,. Clinical considerations in the treatment of acne vulgaris and other inflammatory skin disorders: focus on antibiotic resistance. Cutis 2007; 79 (6 Suppl.): 9-25.
16. Thiboutot DM, Shalita AR, Yamauchi PS, et al. Adapalene gel, 0·1% as maintenance therapy for acne vulgaris: a randomized, controlled, investigator-blind follow-up of a recent combination study. Arch Dermatol 2006; 142: 597-602. (Pubitemid 43727550)
17. Alirezai M, George SA, Coutts I, et al. Daily treatment with adapalene gel 0·1% maintains initial improvement of acne vulgaris previously treated with oral lymecycline. Eur J Dermatol 2007; 17: 45-51. (Pubitemid 46383220)
18. Thielitz A, Sidou F, Gollnick H,. Control of microcomedone formation throughout a maintenance treatment with adapalene gel, 0·1%. J Eur Acad Dermatol Venereol 2007; 21: 747-53. (Pubitemid 46939044)
19. Zhang JZ, Li LF, Tu YT, Zheng J,. A successful maintenance approach in inflammatory acne with adapalene gel 0·1% after an initial treatment in combination with clindamycin topical solution 1% or after monotherapy with clindamycin topical solution 1%. J Dermatolog Treat 2004; 15: 372-8. (Pubitemid 39657848)
20. Pariser DM, Westmoreland P, Morris A, et al. Long-term safety and efficacy of a unique fixed-dose combination gel of adapalene 0·1% and benzoyl peroxide 2·5% for the treatment of acne vulgaris. J Drugs Dermatol 2007; 6: 899-905.
21. Gordon KB, Feldman SR, Koo JY, et al. Definitions of measures of effect duration for psoriasis treatments. Psoriasis Forum 2002; 8: 1-5.
22. Carey W, Glazer S, Gottlieb AB, et al. Relapse, rebound, and psoriasis adverse events: an advisory group report. J Am Acad Dermatol 2006; 54 (4 Suppl. 1): S171-81. (Pubitemid 43238300)
23. Zouboulis CC,. The truth behind this undeniable efficacy-recurrence rates and relapse risk factors of acne treatment with oral isotretinoin. Dermatology 2006; 212: 99-100. (Pubitemid 43260721)
24. Wolf JE,. Maintenance therapy for acne vulgaris: the fine balance between efficacy, cutaneous tolerability, and adherence. Skinmed 2004; 3: 23-6.
25. Zane L,. Acne maintenance therapy: expanding the role of topical retinoids? Arch Dermatol 2006; 142: 638-40. (Pubitemid 43727556)
26. Brand B, Gilbert R, Baker MD, et al. Cumulative irritancy comparison of adapalene gel 0·1% versus other retinoid products when applied in combination with topical antimicrobial agents. J Am Acad Dermatol 2003; 49 (3 Suppl.): S227-32. (Pubitemid 37046537)
27. Caron D, Sorba V, Clucas A, Verschoore M,. Skin tolerance of adapalene 0·1% gel in combination with other topical antiacne treatments. J Am Acad Dermatol 1997; 36: S113-15. (Pubitemid 27265891)
28. Plewig G, Kligman AM,. Acne and Rosacea, 3rd edn. New York: Springer-Verlag, 2000.
29. Webster GF, Leyden JJ, McGinley KJ, McArthur WP,. Suppression of polymorphonuclear leukocyte chemotactic factor production in Propionibacterium acnes by subminimal inhibitory concentrations of tetracyclines and erythromycin. Antimicrob Agents Chemother 1982; 21: 770-2. (Pubitemid 12006526)